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N-Terminal Phosphorylation Sites of Herpes Simplex Virus 1 ICP0
Differentially Regulate Its Activities and Enhance Viral Replication
Heba H. Mostafa, Thornton W. Thompson, David J. Davido
Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA
The herpes simplex virus 1 (HSV-1) infected cell protein 0 (ICP0) is an immediate-early phosphoprotein that transactivates viral
gene expression. Evidence suggests that phosphorylation regulates the functions of ICP0, and three regions (termed regions I, II,
and III) in the protein are known to be phosphorylated. Mutation of the putative phosphorylation sites within region I, termed
Phos 1, which lies in the N-terminal portion of ICP0, impairs the E3 ubiquitin (Ub) ligase and ND10-disrupting activities of
ICP0 in cell culture and diminishes viral replication. To identify the specific phosphorylation site(s) or residues responsible for
the phenotypes observed with Phos 1, individual residues within region I were mutated to alanine (S224A, T226A, T231A, and
T232A) and one double mutant S224A/T226A was constructed. Tissue culture studies demonstrated that the S224A, S224A/
T226A, T231A, and T232A mutants were unable to dissociate the cellular protein PML from ND10 and that the S224/T226A mu-
tant was defective in its ability to dissociate the cellular protein Sp100 from ND10. Additionally, the transactivation activity of
ICP0 was impaired in the S224A and S224A/T226A mutants. The S224A and S224A/T226A mutant forms were more stable than
wild-type ICP0, suggesting that their ability to autoubiquitinate was limited. Moreover, one ICP0 ubiquitination target, USP-7,
was also more stable after infection with these two mutants. Lastly, the replication of the S224A and S224A/T226A mutant vi-
ruses was reduced in cell culture and in vivo. Overall, our data suggest that specific phosphorylation sites within region I differ-
entially regulate the activities of ICP0, which are required for efficient viral replication.
Herpes simplex virus 1 (HSV-1) is a major human pathogenthat infects approximately 80% of the world’s population (1).
HSV-1 infection can range from being asymptomatic to causing
severe diseases such as blindness and encephalitis. As part of its life
cycle, the virus can latently infect the sensory neurons and reacti-
vate from latency by stress. can be reactivated by stress. The lytic
phase of infection is characterized by the expression of the viral
genes in a temporal cascade of immediate-early (IE), early (E), and
late (L) genes (2). The latent phase of infection, on the other hand,
is characterized by the overall lack of productive viral gene expres-
sion, with the exception of the latency-associated transcripts
(LATs) (3). Of the five IE proteins, the phosphoprotein ICP0 (in-
fected cell protein 0) is required for efficient lytic and latent infec-
tions and for reactivation from latency (4–7).
ICP0 is a RING finger motif (8, 9)-containing protein that acts
as a potent transactivator of all three categories of HSV-1 genes
(10), a function that is required for efficient lytic replication (11,
12). The transactivation activity of ICP0 is regulated in part by its
E3 ubiquitin (Ub) ligase activity. The E3 ubiquitin ligase activity of
ICP0 directs the proteosomal degradation of several cellular pro-
teins, two of which, promyelocytic leukemia protein (PML) and
Sp100, are contained in the subnuclear organelle ND10 (nuclear
domain 10) (13–17). ND10 is associated with cellular prolifera-
tion, differentiation, senescence, and apoptosis but is also noted
for possessing antiviral activity (18–21). ICP0-mediated degrada-
tion of ND10-associated proteins disrupts the structure of ND10,
facilitating viral replication (22). Ubiquitin-specific protease 7
(USP-7), which is also called herpesvirus-associated ubiquitin-
specific protease (HAUSP), is another cellular target of ICP0 ubiq-
uitination (23). The relation between USP-7 and ICP0 is unique:
USP-7 initially stabilizes ICP0 levels, and later during infection,
ICP0 directs the degradation of USP-7 (23, 24). In addition to
disrupting ND10 and altering the stability of cellular proteins,
ICP0 impairs the host cell innate and intrinsic antiviral defenses,
which include interferon (25–30) and DNA damage responses
(31, 32), both of which are triggered by viral infection.
ICP0 has been shown to be phosphorylated (33); however, the
exact function phosphorylation plays in regulating its activities is
largely unknown. The observation that specific cellular kinase in-
hibitors impair the transactivating activity of ICP0 suggested a
potential link between phosphorylation and this key activity of
ICP0 (34). Tandem mass spectrometric analysis identified three
regions on ICP0 that are phosphorylated; these are named regions
I, II, and III (35). Mutational analyses of the 11 putative phos-
phorylation residues clustered in the three regions identified re-
gion I as having the greatest impact on ICP0 functions and HSV-1
replication (36, 37). Specifically, clustered mutation of four amino
acid residues in region I (termed Phos 1) impaired the ability of
ICP0 to dissociate two ND10-associated proteins, PML and
Sp100, from ND10, reduced its E3 Ub ligase activity, impaired its
transactivation activity, and impaired acute replication of HSV-1
in cell culture (36). Not surprisingly, Phos 1 mutant virus showed
diminished acute replication and reactivation when tested in a
mouse model of HSV-1 latency and reactivation (37).
In the current study, we wanted to determine which sites in
region I are responsible for the phenotypes observed with Phos 1.
Specifically, we sought to examine the contributions of serine 224
and threonine 226, which have been shown by tandem mass spec-
trometric analyses to be phosphorylated in cell culture (M. C.
Smith, W. S. Lane, and D. J. Davido, unpublished data; M. S.
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Chaurushiya, A. Aslanian, and M. D. Weitzman, unpublished
data), as well as those of the potentially phosphorylated thre-
onines 231 and 232. In addition, we wanted to determine whether
there is differential regulation of the functions of ICP0 through
the phosphorylation or potential phosphorylation of different res-
idues within region I. To address these questions, several phos-
phorylation site mutations (S224A, T226A, S224A/T226A,
T231A, and T232A) were constructed, and the corresponding mu-
tant viruses were generated. Our data indicate that of the four
serines and threonines identified in region I, serine 224 had the
greatest impact on ICP0 functions and viral replication. Interest-
ingly, combined mutation of this site and the threonine 226 site
further reduced the transactivation activity of ICP0 and impaired
its ability to dissociate Sp100 from ND10. Our results strongly
suggest a model in which specific amino acids in region I can
differentially regulate ICP0 activities that are subsequently re-
quired for efficient viral replication.
MATERIALS AND METHODS
Cells and viruses. Vero, Hep-2, and HeLa cells were obtained from the
American Type Culture Collection (ATCC) and were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bo-
vine serum (FBS), 2 mM L-glutamine, 100 g/ml penicillin, and 100 U/ml
streptomycin as described previously (38). L7 cells, a Vero cell line stably
transfected with the HSV-1 ICP0 gene, were grown in the same medium as
Vero cells and were used to determine the titers of all the ICP0 mutant
viruses, including the ICP0-null mutant, 7134 (12). The titers of wild-type
strain KOS (passage 11) and marker rescue (MR) viruses were determined
on Vero cells.
Construction of region I phosphorylation mutations. Plasmid
pAlter-1  ICP0 was used to make all region I mutations by using the
pAlter site-directed mutagenesis kit according to the manufacturer’s pro-
tocol (Promega). The primers (IDT) used for the mutagenesis are S224A
(5=-GGGCCCTGTCGCCCAC-3=), T226A (5=-GTCGCCCACCCACCC-
3=), S224A/T226A (5=-GGGCCCTGTCGCCCACCCACCC-3=), T231A
(5=-CTGAGCCGGCCACGGA-3=), and T232A (5=-CTGAGCCCACCGC
GGA-3=) (underlined letters represent the mutated codon or codons).
Each primer was constructed such that a restriction enzyme site was cre-
ated or eliminated. Mutations were identified by restriction enzyme digest
analyses and were confirmed by DNA sequencing. The double site muta-
tion was made because these sites are phosphorylated in HSV-1 ICP0 and
are conserved between the ICP0 homologues of HSV-1 and HSV-2 (M. C.
Smith and D. J. Davido, unpublished data).
Generation of ICP0 phosphorylation mutant viruses. Region I mu-
tant viruses were created by marker transfer. Briefly, Vero cells were plated
on 60-mm dishes at 4  105 cells per plate, and 24 h later, cells were
cotransfected with 1 g of 7134 viral DNA and 2.5 g of pAlter-1 express-
ing mutant forms of ICP0 digested with EcoRI and HindIII. Transfections
were carried out by using Fugene 6 or Fugene HD (Roche) at a ratio of 3:1
(l of transfection reagent per g of DNA) according to the manufactur-
er’s recommendations. Mutants were identified by blue/white selection.
White plaques were picked and purified in at least 3 rounds in the presence
of 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal). Insertion
of region I mutations was initially identified by PCR and restriction en-
zyme digestions (see Fig. 4) and was confirmed by restriction enzyme
digestion and Southern blot analyses. Marker rescue viruses were gener-
ated by cotransfecting the mutant viral genomic DNA with plasmid
pAlter-1  ICP0 digested with EcoRI and HindIII. Rescuants were iden-
tified by PCR amplification of region I and restriction enzyme and/or
Southern blot analyses. All the marker rescue viruses were plaque purified
at least 3 times.
Immunofluorescence studies. (i) ND10 and ICP0 staining. Hep-2
cells were plated on glass coverslips in 12-well plates for 24 h (5  104 cells
per well). Cells were then transfected with 1 g of plasmid DNA and
Fugene 6 or Fugene HD using a 3:1 dilution ratio as described above.
Sixteen to 18 h posttransfection, cells were fixed with 5% formaldehyde
and 2% sucrose in phosphate-buffered saline (PBS) for 5 min, washed
with PBS, and permeabilized in 0.5% NP-40 and 10% sucrose in PBS for
15 min at 4°C. Cells were washed and blocked with PBS-FB (PBS, 1% fetal
bovine serum, 1% bovine serum albumin [BSA], and 0.05% sodium
azide) for 1 h at 37°C. The primary antibodies used were a mouse mono-
clonal antibody against ICP0 (11060; catalog no. sc-53070; Santa Cruz
Biotechnology) diluted 1:500 and a rabbit polyclonal antibody against
PML (A301-167A; Bethyl Laboratories) diluted 1:100 or a rabbit poly-
clonal antibody against Sp100 (AB1380; Chemicon International) diluted
1:100. Cells were incubated in primary antibodies for 30 min at 37°C and
were then washed at least 3 times. Each secondary antibody was added for
30 min at 37°C. The secondary antibodies used were a DyLight 594-con-
jugated donkey anti-rabbit antibody (catalog no. 711-515-152; Jackson
ImmunoResearch) diluted 1:1,000 and a DyLight 488-conjugated donkey
anti-mouse antibody (catalog no. 715-295-151; Jackson Immuno-
Research) diluted 1:1,000. Cells were then washed 3 times with PBS,
mounted with the ProLong Antifade kit (Invitrogen), and examined by
immunofluorescence microscopy (with a Nikon Eclipse TE-2000-U4 mi-
croscope).
(ii) Subcellular localization of ICP0. HeLa and Hep-2 cells were in-
fected at a multiplicity of infection (MOI) of 4 with KOS, 7134, Phos1, or
each region I phosphorylation mutant for 4 or 8 h and were fixed, perme-
abilized, and stained for ICP0 as described above.
(iii) PIAS-1 localization. Hep-2 cells were plated (5  104 per well)
onto glass coverslips in a 24-well plate for 24 h. The cells were then trans-
fected with 0.5 g of plasmid DNA using Fugene HD at a ratio of 3:1.
Sixteen hours posttransfection, samples were fixed with 4% formaldehyde
in PBS for 15 min and were blocked for 1 h in 5% normal goat serum and
0.2% Triton X-100 diluted in PBS. The anti-ICP0 mouse monoclonal
antibody (11060; catalog no. sc-53070; Santa Cruz Biotechnology) was
diluted 1:500, and the primary rabbit polyclonal antibody against PIAS-1
(protein inhibitor of activated STAT 1), kindly provided by Yoshi Azuma,
was diluted 1:200. The staining proceeded as described above in the
“ND10 and ICP0 staining” section.
Luciferase assays. Vero, Hep-2, or HeLa cells were plated at 5  104
per well in 24-well plates for 24 h. Cells were cotransfected either with 50
ng of the reporter plasmid (VP16 promoter-luciferase construct) (39)
alone or with 100 ng of pAlter-1 (empty plasmid), pAlter-1  ICP0, or a
pAlter-1 construct expressing one of the region I site mutations, and
salmon sperm DNA was added for a total of 1 g per well. Transfections
were performed according to the manufacturer’s protocol using Fugene
HD or X-tremeGENE 9 (Roche) at a ratio of 3:1. Cells were transfected for
48 h; wells were washed with PBS; and each well was then harvested in 100
l of 1 passive lysis buffer (PLB) (catalog no. E1941; Promega) by rock-
ing at room temperature for 15 min. Samples were harvested, vortexed for
30 s, and briefly centrifuged at room temperature. Twenty microliters of
each sample was used for each assay. Luciferase assays were conducted
using Promega luciferase assay system 1000 (catalog no. E4550): 100 l of
luciferase assay reagent was added per sample, with a 2-s delay before a
10-s read (Synergy HT multimode microplate reader; BioTek). Light units
are displayed as percentages normalized to the wild-type value, and sta-
tistical analyses were performed using the Mann-Whitney U test.
Western blot and immunoprecipitation analyses. (i) ICP0 stability.
A total of 1  105 HeLa or Hep-2 cells were plated per well in a 12-well
plate. Twenty-four hours postplating, cells were infected at an MOI of 2
for each virus in triplicate wells. Samples were harvested at 4, 6, and 8 h
postinfection in 50 l 1 Laemmli buffer (100°C) supplemented with 1
protease inhibitors (leupeptin at 1 g/ml, aprotinin at 1 g/ml, phenyl-
methylsulfonyl fluoride [PMSF] at 1 mM) and 1 phosphatase inhibitor
cocktail (catalog no. P2850; Sigma). The 6- and 8-h samples were treated
with 100 g/ml of cycloheximide (CHX) at the 4-h time point. Samples
were heated at 95°C for 5 min, vortexed, and centrifuged. Ten microliters
per sample was loaded onto a 6% sodium dodecyl sulfate-polyacrylamide
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gel electrophoresis (SDS-PAGE) gel and was run at 120 V for 1 h. Proteins
were transferred to nitrocellulose membranes by using a semidry transfer
unit (catalog no. TE77; GE Healthcare). Each membrane was blocked in
2% nonfat dry milk in Tris-buffered saline (TBS) and 0.05% Tween 20
(TBS-T) for 1 h at room temperature and was then cut into two parts to
probe for ICP0 and -actin. To detect ICP0, mouse monoclonal antibody
11060 (catalog no. sc-53070; Santa Cruz Biotechnology) was diluted
1:1,000 in 2% nonfat dry milk in TBS-T overnight at 4°C. -Actin was
detected with a rabbit polyclonal antibody (catalog no. sc-1616; Santa
Cruz Biotechnology) diluted 1:1,000 in 2% nonfat dry milk in TBS-T. The
membranes were washed 3 times in TBS-T, and the following secondary
antibodies were added and incubated at room temperature for 1 h: a
peroxidase-conjugated goat anti-rabbit antibody (catalog no. 111-035-
144; Jackson ImmunoResearch) diluted 1:1,000 and a peroxidase-conju-
gated goat anti-mouse antibody (catalog no. 205-035-108; Jackson
ImmunoResearch) diluted 1:1,000. Membranes were washed 3 times in
TBS-T and were developed using SuperSignal West Pico chemilumines-
cent substrate (catalog no. 34087; Thermo Fisher Scientific). Pictures were
captured with a Kodak 4000R image station, and the band intensities were
measured by densitometry.
(ii) USP-7 levels. Hep-2 or HeLa cells were infected, and samples were
processed as described for the ICP0 stability experiment above except that
the cells were not treated with cycloheximide. Samples were separated on
10% SDS-PAGE gels, and membranes were blocked in 5% BSA in TBS
containing 0.1% Tween 20 for 1 h at room temperature. Probing for
USP-7 was performed by using a rabbit monoclonal antibody against
HAUSP (catalog no. 4833; Cell Signaling) diluted 1:1,000 in TBS contain-
ing 5% BSA and 0.1% Tween at 4°C overnight.
(iii) PIAS-1 protein levels. Infection of Hep-2 or HeLa cells, sample
processing, and transfer of proteins to membranes were performed as
described for the USP-7 studies above, except that blocking was done in
5% milk in TBS with 0.1% Tween 20 for 1 h at room temperature. The
primary rabbit polyclonal antibody against PIAS-1 was kindly provided
by Yoshi Azuma and was diluted at 1:500.
(iv) USP-7 interaction studies. Hep-2 or HeLa cells were plated in
60-mm dishes at 5  105 cells per dish. Twenty-four hours later, the cells
were either mock infected or infected with KOS or Phos 1 at an MOI of 5
for 4 h. Plates were washed once with PBS, and cells were harvested in 100
l of a buffer containing 100 mM Tris-HCl (pH 8), 50 mM NaCl, 10%
glycerol, 20 mM -mercaptoethanol, and 1% Nonidet P-40 with protease
and phosphatase inhibitors as described above. Samples were sonicated at
100 W for 30 s, incubated on ice for 30 min, and centrifuged at 15,000 rpm
for 10 min at 4°C. Fifty microliters of protein G Dynabeads (catalog no.
77149610; Invitrogen) were incubated in 200 l of PBS containing 0.05%
Tween 20 and 4 l of a rabbit polyclonal antibody against ICP0 (Pacific
Immunology) by rotation for 1 h at room temperature. Beads bound to
the antibody were washed with PBS and 0.05% Tween 20 and were incu-
bated with the sample lysates by rocking at 4°C overnight. The beads were
then washed twice with PBS-Tween and were transferred to new tubes.
Fifty microliters of 1 Laemmli buffer (100°C) with protease and phos-
phatase inhibitors was added to each sample, and samples were boiled for
5 min, vortexed, boiled again, and vortexed twice for 1 min each time.
Western blot analyses were performed as described above in the “USP-7
levels” section, and band intensities were measured by densitometry.
De novo viral replication assays. De novo viral replication assays were
carried out as described previously (36). Briefly, Vero cells were plated in
12-well plates (1  105 cells per well) for 24 h. Two hours before trans-
fection, fresh Vero cell medium was added to each well. Transfections
were carried out in duplicate by using 125 ng infectious viral DNA and 625
ng salmon sperm DNA per well, diluted in Opti-MEM (Invitrogen).
Fugene 6 or Fugene HD was used for transfections at a 3:1 ratio (3 l of the
transfection reagent to 1 g of DNA). The transfection mixture was added
to each well, which contained 0.5 ml Opti-MEM, for 5 h at 37°C, and was
then replaced with fresh Vero cell medium. Samples were harvested 48 h
later. The titer of wild-type virus was determined on Vero cells, and the
titers of all ICP0 mutants were determined on L7 cells. The replication of
KOS was assigned the value of 100%, and the replication of all the mutant
viruses was normalized to that of KOS. Statistical analyses were performed
using the Mann-Whitney U test.
Acute viral replication in TG and eyes. Infections were carried out as
published previously (37). Briefly, outbred CD-1 female mice (6 to 7 weeks
old) were purchased from Charles Rivers Laboratories (Shrewsbury, MA)
and were cared for according to the Guide for the Care and Use of Laboratory
Animals (40). The protocol for using these mice is approved by the University
of Kansas Institutional Animal Care and Use Committee. Mice were anesthe-
tized by intraperitoneal injection of ketamine (75 to 100 mg/kg of body
weight) and xylazine (10 mg/kg of body weight). The corneas of the mice were
scarified with a 26-gauge needle and were infected with either KOS, the 7134,
Phos 1, S224A, T226A, S224A/T226A, T231A, or T232A mutant, or each
marker rescue virus at 2  105 PFU of virus per eye in 3 to 5 l medium. For
the determination of acute titers in the trigeminal ganglia (TG), the mice were
euthanized by CO2 asphyxiation at day 5 postinfection, and TG were re-
moved and placed in microcentrifuge tubes containing 500 l of 1% FBS
growth medium and 100 l of 1-mm glass beads. Samples were homogenized
with a Mini-BeadBeater 8 (BioSpec). To determine the acute titers in the eyes,
the eyes of the mice were swabbed using cotton-tipped swabs at day 5 postin-
fection, and the swabs were placed in microcentrifuge tubes containing 500l
of 5% FBS growth medium. The titers of the wild-type and rescuant viruses
were determined on Vero cells, and the titers of all ICP0 mutant viruses were
determined on L7 cells. Statistical analyses were performed using the Student
t test.
RESULTS
Dissociation of two ND10 components is differentially regu-
lated by distinct phosphorylation sites in region I of ICP0. In a
previous study, we showed that Phos 1, in contrast to wild-type
ICP0, is unable to dissociate PML and Sp100 from ND10 in tran-
FIG 1 Region I phosphorylation site mutations. (A) ICP0 functional domains
with three characterized phosphorylation regions (I, II, and III), adapted from
reference 35. (B) Amino acid sequences of region I and each region I phos-
phorylation site mutant. All mutated residues are underlined. The slash in
region I indicates the boundary between the second and third exons of ICP0.
HSV-1 ICP0 Phosphorylation
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sient-transfection assays (36). To determine which sites in the
Phos 1 mutant form of ICP0 mediate the dissociation of these two
proteins, we transfected Hep-2 cells with plasmids that express
each region I phosphorylation site mutation or the double muta-
tion (Fig. 1), and the localization of ICP0 and PML, or of ICP0 and
Sp100, was examined by immunofluorescence. As shown in
Fig. 2A, wild-type ICP0 did not colocalize with PML, dissociating
it from ND10. Of the region I mutant forms that were examined,
only the T226A mutant behaved like wild-type ICP0. As reported
previously (36), Phos 1 was unable to efficiently dissociate PML
from ND10 (Fig. 2A and C). All other region I phosphorylation
site mutant forms of ICP0 (the S224A, S224A/T226A, T231A, and
T232A mutants) were as impaired as Phos 1 in dissociating PML
from ND10. Of these, the T232A mutant colocalized with PML,
FIG 2 Region I phosphorylation site mutations and ND10 staining. (A and B) Localization of PML (A) or Sp100 (B) and wild-type (Wt) ICP0 or region I
phosphorylation site mutant forms of ICP0. Hep-2 cells were transfected with plasmids expressing Wt ICP0, Phos 1, each region I phosphorylation site mutation,
or the double site mutation. Sixteen hours posttransfection, the cells were fixed, stained for ICP0 and either PML (A) or Sp100 (B), and examined by fluorescence
microscopy. (C and D) Graphs showing the percentages of ICP0-expressing cells that colocalized with PML (C) or with Sp100 (D). In both experiments, at least
100 ICP0-expressing cells were examined for each form (Wt or mutant) of ICP0.
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but PML staining appeared to be less intense than that in mock-
transfected cells, indicating that this mutant form of ICP0 may
retain a degree of PML-dissociating activity. In contrast to the
results with PML, all region I phosphorylation site mutants were
capable of dissociating Sp100 from ND10 similarly to wild-type
ICP0, except for the S224A/T226A double mutant, which behaved
like Phos 1 and was unable to disperse Sp100 (Fig. 2B and D). Our
data show that different phosphorylation residues in region I of
ICP0 regulate the dissociation of PML from ND10 versus the dis-
sociation of Sp100 in Hep-2 cells.
The transactivation activity of ICP0 is regulated by serine
224. A previous report indicated that the transactivation activity
of ICP0 in cell culture is reduced for Phos 1 (35). To test the
transactivation activity of region I phosphorylation site mutant
forms of ICP0, Vero cells were transfected with an HSV-1 VP16
promoter-luciferase reporter construct either alone or in combi-
nation with a plasmid expressing wild-type ICP0 or each region I
mutation. Forty-eight hours posttransfection, cells were lysed and
assayed for luciferase activity, with the wild-type ICP0 assigned a
value of 100%. As expected, Phos 1 was unable to efficiently in-
duce the expression of the VP16 promoter, and its induction abil-
ity was 16% of the level of wild-type ICP0 (P  0.029) (Fig. 3). Of
all the other mutants tested, only the S224A and S224A/T226A
mutants showed significant decreases in transactivation activity,
with levels that were 43% (P  0.02) and 17% (P  0.02) of the
level wild-type ICP0, respectively. Induction of the VP16 pro-
moter by the T226A, T231A, and T232A mutants was not im-
paired. Thus, S224 contributes to the transactivation activity of
ICP0 in combination with T226 to enable the maximal transacti-
vation function of ICP0. Similar results were observed in two
other cell lines (HeLa and Hep-2 cells) (H. H. Mostafa and D. J.
Davido, unpublished data).
Construction of region I mutant viruses. In order to charac-
terize the role of region I sites in the context of lytic replication,
our region I mutations were introduced into the viral genomes
as described in Materials and Methods, creating mutant vi-
ruses. The ICP0-null mutant 7134 was used to make each mu-
tant by marker transfer. For each mutant, a marker rescue virus
was made to ensure that any phenotype observed was not due
to secondary mutations in the viral genome. The insertion of
restriction digestion sites during the construction of each mu-
tant helped us identify mutant viruses either by Southern blot-
ting or by PCR (Fig. 4).
De novo replication of S224A and S224A/T226A mutant vi-
ruses is reduced. Phos 1 showed impaired de novo replication in
tissue culture (36); consequently, we wanted to determine which
region I site(s) is responsible for this phenotype. To answer this
question, we examined de novo replication of region I mutant
viruses. Notably, in the absence of the HSV IE transactivator
VP16, ICP0 transactivating activity is required for high levels of
de novo replication (12). For this experiment, Vero cells were
transfected with infectious viral DNA from wild-type HSV-1
(strain KOS), the ICP0-null mutant 7134, or each phosphory-
lation site mutant. As expected, 7134 replication was reduced
5  105-fold from that of KOS, a finding similar to a previous
report (36). The Phos 1 mutant showed a 14-fold decrease, and
of the region I mutants, only the S224A and S224A/T226A
mutants showed significant reductions, of 9-fold and 16-fold,
respectively (P  0.009 for both), relative to KOS (Table 1).
Taken together, our data indicate that S224 is required for
efficient de novo viral replication.
Serine 224 regulates the E3 ubiquitin ligase activity of ICP0.
(i) ICP0 protein stability. The Phos 1 mutant form of ICP0 was
previously shown to have greater stability than wild-type ICP0
(36), indicative of alterations in the E3 ubiquitin ligase activity of
ICP0. To identify sites in region I that contribute to the stability of
Phos 1, we infected HeLa cells in triplicate with KOS, Phos 1, or
each region I mutant. After 4 h of infection, one well was har-
vested, while the remaining two wells were blocked with the pro-
tein synthesis inhibitor cycloheximide for an additional 2 or 4 h
and were subsequently harvested. ICP0 and actin protein levels
were examined by Western blotting. As shown in Fig. 5, the Phos
1, S224A, and S224A/T226A mutants were more stable than wild-
type ICP0. The phenotype observed for these three mutants sug-
gests that S224 controls the autoubiquitination of ICP0. Similar
results were observed in Hep-2 cells (H. H. Mostafa and D. J.
Davido, unpublished data).
(ii) USP-7 levels. To confirm that the Phos 1, S224A, and
S224A/T226A mutations impaired the E3 ubiquitin ligase ac-
tivity of ICP0, we examined the protein levels of another target
of ICP0 ubiquitination, USP-7. In this experiment, HeLa cells
were either mock infected or infected with KOS or the 7134,
Phos 1, S224A, or S224A/T226A mutant for 4, 6, or 8 h. The
cells were then harvested, and the protein levels of USP-7,
ICP0, and actin were determined by Western blotting. As re-
ported previously for wild-type HSV-1 (23), KOS infection
reduced USP-7 protein levels (Fig. 6). In contrast, USP-7 pro-
tein levels were comparable over time in mock-infected cells
and cells infected with the 7134, Phos 1, S224A, or S224A/
T226A mutant (Fig. 6). Because it has been shown before that
the interaction between ICP0 and USP-7 mediates the stabili-
zation of ICP0 early during lytic infection (24), we wanted to
address the possibility that the higher stability of the Phos1
mutant form and/or the higher stability of USP-7 following
Phos 1 infection may be due to alterations in the interaction
between Phos 1 and USP-7. For this experiment, we took KOS-
or Phos 1-infected cell extracts from HeLa cells 4 h postinfec-
tion and determined the extent to which USP-7 coimmunopre-
cipitated with ICP0 in these extracts. By accounting for the
amount of Phos 1 that was immunoprecipitated, our data show
that Phos 1 pulled down USP-7 to an extent similar to that for
FIG 3 Transactivation activities of region I phosphorylation site mutations.
Vero cells were transfected for 48 h with an HSV-1 reporter plasmid (pGL3-
VP16; 50 ng) and a plasmid expressing either wild-type (wt) ICP0, Phos 1, one
of the region I phosphorylation site mutations, or the double site mutation.
Luciferase assays of cell extracts were performed to monitor the transactivating
activity of ICP0. *, P  0.05 by the Mann-Whitney U test. Error bars indicate
the standard errors of the means for all samples.
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wild-type ICP0 (Fig. 7). Consequently, these data do not sup-
port the hypothesis that an increase in the stability of Phos 1 is
mediated by an increase in its interaction with USP-7. Similar
results were obtained with Hep-2 cells (H. H. Mostafa and D. J.
Davido, unpublished data). Taken together, our data support the
conclusion that the Phos 1, S224A, and S224A/T226A mutants
have impaired E3 ubiquitin ligase activity, and they indicate that
S224 regulates this activity of ICP0.
FIG 4 Construction of ICP0 region I phosphorylation mutant viruses. Region I phosphorylation mutant viruses were constructed by marker transfer as
described in Materials and Methods. (A) Restriction enzyme digestion patterns, with the fragment lengths (in base pairs), of KOS and region I phosphorylation
mutants. Note that the S224A/T226A mutant contains both BfaI and NgoMIV sites. The restriction pattern shown for the T232A mutant is from a PCR product.
(B) Southern blots of KOS and the Phos 1, T226A, S224A/T226A, and T231A mutants digested with NgoMIV (lanes 1 to 5, respectively) and of KOS and the Phos
1, S224A, and S224A/T226A mutants digested with BfaI (lanes 6 to 9, respectively). (C) Twelve percent polyacrylamide gel of KOS (lane 1) and T232A mutant
(lane 2) PCR products digested with SacII.
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The subcellular localization of region I phosphorylation mu-
tants is similar to that of wild-type ICP0. In order to examine the
possibility that the subcellular localization of these mutant forms
of ICP0 may be altered, thus altering the activities of ICP0, HeLa
and Hep-2 cells were infected with either KOS, Phos 1, or each of
the region I phosphorylation site mutants. The localization of
ICP0 was determined at 4 and 8 h postinfection. All the mutants
showed localization patterns similar to that of wild-type ICP0 in
the two cell lines tested, with primarily nuclear localization at 4 h
postinfection and both nuclear and cytoplasmic localization at 8 h
postinfection (Fig. 8).
Serine 224 is required for efficient acute viral replication in
the TG of mice. We showed previously that Phos 1 replication in
the trigeminal ganglia (TG) during the acute phase of infection
was significantly lower than that of wild-type KOS, with the max-
imal decrease observed at day 5 postinfection (37). To test which
residues in region I are required for efficient in vivo replication,
CD-1 mice were infected with KOS, Phos 1, each region I phos-
phorylation site mutant, and corresponding marker rescue vi-
ruses. Five days postinfection, mice were swabbed and were then
sacrificed, TG were explanted, and acute viral replication was
monitored by a standard plaque assay. Acute replication in the
eyes on day 5 showed only slight reductions for the S224A mutant
(5-fold [P  0.005]) and Phos 1 (11-fold [P  0.00012]), whereas
all the other region I mutants replicated to levels comparable to
that of wild-type HSV-1. With regard to productive infection of
the trigeminal ganglia, as expected, 7134 and Phos 1 showed sig-
nificantly lower replication levels (650-fold [P  1.2  1018] and
11-fold [P  2  106], respectively) than that of KOS (Fig. 9A).
The replication of the S224A and S224A/T226A mutants was re-
duced by 48-fold (P  1.9  1011) and 15-fold (P  1.8  108),
respectively, whereas the replication of the T226A, T231A, and
T232A mutants (Fig. 9A) and of the marker rescue viruses (Fig.
9B) was similar to that of KOS. Our results demonstrate that S224
enhances productive infection in the TG of mice.
DISCUSSION
Phosphorylation is a posttranslational modification that regulates
the activities of many viral proteins (41, 42). ICP0 has been shown
to be heavily phosphorylated (33), and previous studies from our
lab strongly support the hypothesis that phosphorylation regu-
lates its activities (35–37). Because four amino acids in region I of
ICP0 have been shown to play an important role in regulating its
activities and viral replication, we performed mutagenesis of a
specific site or sites in this region in order to identify residues that
are required for the activities of ICP0. Specifically, region I has
been shown to be phosphorylated at one or two residues (35), and
it has been determined recently by our lab and by other investiga-
tors that S224 and T226 are phosphorylated. Characterization of
FIG 6 USP-7 levels observed with region I phosphorylation site mutants.
HeLa cells were either mock infected or infected with the KOS, 7134, Phos 1,
S224A, or S224A/T226A virus at an MOI of 2 for 4, 6, or 8 h. ICP0, USP-7, and
actin protein levels were determined by Western blot analyses.
FIG 7 Interaction of ICP0 and Phos 1 with USP-7. HeLa cells were either
mock infected (lanes 1 and 4) or infected with KOS (lanes 2 and 5) or Phos 1
(lanes 3 and 6). Four hours postinfection, ICP0 was immunoprecipitated, and
the levels of ICP0, USP-7, and actin were analyzed by Western blotting.
TABLE 1 De novo replication of region I mutantsa
Virus
Titer (% relative to
the titer of KOS)
Fold difference
from KOSb
KOS 100
7134 0.0002 25  105
Phos 1 mutant 6.9 214.5
S224A mutant 11.1 29.05
T226A mutant 79.9 21.25
S224A T226A mutant 6.2 216.1
T231A mutant 128.2 10.78
T232A mutant 130.3 10.77
a Vero cells were transfected with infectious viral DNA of wild-type HSV-1 (strain
KOS), an ICP0-null mutant (7134), and region I mutants. At 48 h posttransfection,
cells were harvested, and titers of viruses were determined by a standard plaque assay.
Mutants whose viral replication was significantly lower than that of KOS were tested
with two independent viral DNA preparations. The experiment was repeated five times,
and the data presented are the means.
b2, reduction;1, increase.
FIG 5 ICP0 stability of region I phosphorylation site mutants. HeLa cells were
infected with the indicated viruses at an MOI of 2. Four hours postinfection,
cells were harvested, and duplicate samples were treated with cycloheximide
(CHX; 100 g/ml) and were harvested at 6 and 8 h postinfection. ICP0 and
actin levels were determined by Western blot analyses.
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these mutations in the absence of other viral factors indicates that
S224 phosphorylation is important for efficient dissociation of
PML from ND10 (Fig. 2A and C), and it appears that the phos-
phorylation of either S224 or T226 is sufficient for efficient Sp100
dissociation (Fig. 2B and D). Interestingly, T231 and T232 also
play an important role in the dissociation of PML (Fig. 2A and C),
but neither is required for Sp100 dissociation (Fig. 2B and D),
suggesting a potential structural role for these residues in dissoci-
ating PML from ND10. S224 is also required for optimal levels of
ICP0-mediated transactivation activity in luciferase reporter as-
says (Fig. 3). In the context of viral infections, we showed that S224
is important for efficient E3 ubiquitin ligase activity (Fig. 5 and 6)
and for viral replication both in tissue culture (Table 1) and in the
trigeminal ganglia of mice (Fig. 9A). Our data highlight S224,
which is in close proximity to the RING finger motif of ICP0 (Fig.
1), as the residue in region I that has the major impact on the
activities of ICP0.
To understand the mechanism by which phosphorylation
regulates the functions of ICP0, particularly its E3 Ub ligase
activity, we propose the hypothetical model shown in Fig. 10.
As a RING finger-containing E3 ubiquitin ligase, ICP0 acts as a
scaffold, binding both the E2 ubiquitin-conjugating (Ubc) en-
zyme and its substrates, thereby facilitating ubiquitin chain
transfer and conferring substrate specificity. Given that phos-
phorylation regulates the action of many E3 ubiquitin ligases,
activating (43, 44) or inactivating (45) them, it is possible that
the E3 Ub ligase activity of ICP0 is regulated by phosphoryla-
tion, enhancing its contact with a particular substrate or E2
enzyme (Fig. 10A). Our data demonstrate that Phos 1 is not
detectably altered from wild-type ICP0 in its interaction with
one of its substrates, USP-7 (Fig. 7). Although this finding does
not exclude the possibility that phosphorylation in region I can
affect the binding of ICP0 to other target substrates, it suggests
another possibility, that phosphorylation promotes the inter-
action of ICP0 with a particular E2 Ubc enzyme. In a prelimi-
nary experiment, we examined the colocalization of wild-type
ICP0 or Phos 1 with the E2 enzyme UbcH5a. UbcH5a has been
shown to be one of two E2 Ubc’s of ICP0 that direct the ubiq-
FIG 8 Subcellular localization of the ICP0 protein in region I phosphorylation site mutants. HeLa and Hep-2 cells were infected with KOS or one of the region
I phosphorylation mutants for 4 or 8 h. The cells were fixed, stained for ICP0, and examined by fluorescence microscopy.
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uitination of selected ICP0 targets in vitro and in cell culture
(46–48). Our initial results show extensive colocalization be-
tween wild-type ICP0 and UbcH5a, whereas Phos 1 did not
colocalize extensively with UbcH5a (H. H. Mostafa and D. J.
Davido, unpublished data). This suggests that Phos 1 may be
impaired in its interaction with UbcH5a compared to wild-
type ICP0. Ongoing studies will determine the extent of the
role that region I plays in facilitating the interaction of ICP0
with the E2 Ubc enzymes, such as UbcH5a, and will specifically
test the role of the S224 site in facilitating such interactions.
The increased stability of Phos 1 may also be attributed to
alterations in its interactions with the E2 enzymes or the cellular
E3 ubiquitin ligase SIAH-1. In the latter case, the binding of
SIAH-1 to ICP0 has been shown to decrease the stability of ICP0
(49). This raises the question of whether SIAH-1 binding by the
Phos 1 mutant form of ICP0 is diminished, resulting in a more
stable protein. This argument is supported by a recent publication
showing that the binding of ICP0 to another cellular E3 ubiquitin
ligase, RNF8, is dependent on ICP0 phosphorylation (50). Inter-
estingly, the phosphorylation of ICP0 at an N-terminal residue
specifically directed the degradation of RNF8, whereas the degra-
dation of other ICP0 targets was unaffected. In addition, ICP0, like
its other alphaherpesvirus orthologues (e.g., varicella-zoster virus
ORF61 [51]), is capable of autoubiquitination, although whether
this occurs via intramolecular interactions or intermolecular in-
teractions through dimerization (52), and the role of phosphory-
lation in either mechanism, is currently unknown. Thus, the rela-
tionships between ICP0 phosphorylation and SIAH-1 binding
and ICP0 phosphorylation and its autoubiquitination remain to
be determined (Fig. 10B).
The impairment of PML and Sp100 dissociation was observed
with Phos 1 and other region I phosphorylation site mutations in
the absence of other viral factors in transient-transfection assays
(Fig. 2) (36) but not during the course of viral infection (36; also
H. H. Mostafa and D. J. Davido, unpublished data). These results
indicate that other viral factors and/or the level of their expression
likely compensates for the defect of region I mutants in dissociat-
ing these two ND10-associated proteins. On the other hand, al-
though it has been shown previously that the dispersal of PML and
Sp100 mediated by ICP0 is dependent on the E2 enzyme UbcH5a
in cell culture (48), ICP0 was unable to ubiquitinate SUMOylated
PML in vitro (47). The latter result suggests that other factors are
required for the ICP0-directed ubiquitination of PML (and po-
tentially Sp100). Also, our data show that the regulation of PML by
individual mutant forms of ICP0 differs from their regulation of
Sp100. A similar result was observed in a previous study from our
laboratory in which another ICP0 phosphorylation mutant, Phos
2, could dissociate Sp100 but not PML from ND10 in transient-
transfection assays (36). For our region I mutant forms of ICP0,
we hypothesize that distinct cellular factors regulate the dissocia-
FIG 9 Acute replication of region I phosphorylation site mutants in the trigeminal ganglia (TG) of mice at day 5 postinfection. CD-1 mice were infected with 2 
105 PFU per eye. Five days postinfection, mice were sacrificed; TG were removed and homogenized; and viral titers were determined by standard plaque assays.
(A) Replication of region I phosphorylation site mutants. *, P  0.05 by Student’s t test. (B) Replication of region I phosphorylation mutant marker rescue
viruses. Error bars represent the standard errors of the means. The dashed lines indicate the minimum limit of detection. Eight mice were used per virus.
FIG 10 Hypothetical models of the mechanism by which the E3 ubiquitin ligase activity of ICP0 is controlled by phosphorylation. (A) Phosphorylation (P) can
regulate the interaction of ICP0 with a target substrate or an E2 ubiquitin (Ub)-conjugating enzyme. (B) The ubiquitination of ICP0 is regulated by phosphor-
ylation, which enhances intramolecular or intermolecular autoubiquitination or binding to cellular E3 ubiquitin ligases, such as SIAH-1.
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tion of PML and that of Sp100. In an attempt to determine what
factors could potentially contribute to ICP0-directed PML disso-
ciation, we looked at the staining pattern and protein levels of
PIAS-1, as well as its interaction with ICP0 after transient trans-
fection and infection. The E3 SUMO-ligase PIAS-1 has recently
been shown to regulate the degradation of PML (53), and its loss
results in increased PML stability. Our studies showed that the
expression of wild-type ICP0 or Phos 1 did not influence the stain-
ing of PIAS-1 in transient assays (Fig. 11A) or PIAS-1 protein
levels during infection (Fig. 11B). We did not detect interactions
between ICP0 and PIAS-1 by coimmunoprecipitation assays
(H. H. Mostafa and D. J. Davido, unpublished data). We propose
that the dissociation of PML directed by ICP0 is not dependent on
ICP0 interacting with PIAS-1.
Many questions remain as to how phosphorylation regulates
the activities of ICP0. For example, how does phosphorylation of
ICP0 differentially regulate its activities during acute infection in
vivo? And what are the kinases that contribute to the phosphory-
lation of ICP0? Previous work has shown that the phosphorylation
status of ICP0 is altered along the course of viral replication (33,
54) and is dependent on the viral kinase UL13 (55) and cellular
cyclin-dependent kinases (cdk’s) (34). Ongoing work in our lab is
aimed at identifying the kinases that phosphorylate and control
the activities of ICP0.
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